RxDoctor Payments Data

Gail Sullivan, MD

Gynecology · Philadelphia, PANPI 1245247501

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.1% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 36.0% of the total. That places this record below the midpoint for gynecology clinicians in PA, where the typical reported total is $657.

$628in general payments, 2019–2025

Across 33 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$226
  • Boehringer Ingelheim$86
  • Novo Nordisk$66
  • AMAG Pharmaceuticals, Inc.$44
  • Millicent US Inc$29
  • Kowa Pharmaceuticals America, Inc.$29
  • plus $148 from 9 others

What the payments were for

  • Food & beverage$58493%
  • Education$447%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$628 in reported general payments places this provider in the 45th percentile of 98 gynecology providers in Pennsylvania.

See all gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$15,478
Medicare patients
135
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated27$11,751
OsphenaOspemifene17$9,299
Estradiol102$4,554
Tolterodine Tartrate ErTolterodine Tartrate11$1,381
ValacyclovirValacyclovir Hcl30$852
Raloxifene Hcl15$835
Estradiol (Once Weekly)Estradiol13$698
Fluconazole46$390
Terconazole12$343
Norethindrone Acetate20$336
Metronidazole13$255
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet15$251
Hailey FeNorethindrone-E.Estradiol-Iron12$173
Triamcinolone Acetonide20$113
Nystatin11$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$15$11,75127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 98 gynecology providers in Pennsylvania.

Other gynecology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →